acute myeloid leukemia
Conditions
Interventions
experimental group :D-CAG+VEN
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1.Patients with acute myeloid leukemia (AML) diagnosed by bone marrow morphology and immunophenotyping (in line with WHO 2016 diagnostic criteria), including newly treated AML, secondary AML (MDS/MPN transformation AML and treatment-related AML) and relapsed AML; 2.Age =60 years old, or<60 years old AML patients with unfit intensive chemotherapy; 3.Obtain informed consent signed by the patient or legal representative.
Exclusion criteria
Exclusion criteria: 1.Acute promyelocytic leukemia (APL) at the bone marrow morphology or molecular level; 2.Allergy to any drug involved in the program; 3.Other serious medical conditions that may limit patients' participation in the study (such as advanced infection, uncontrolled diabetes, severe cardiac insufficiency or angina, severe liver dysfunction, etc.) 4.Patients who are participating in other clinical trials; 5.Unable to understand or follow the research protocol; 6.Other conditions that the researcher considers inappropriate for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete remission; | — |
Secondary
| Measure | Time frame |
|---|---|
| 1-year progression-free survival;1-year overall survival; | — |
Countries
china
Contacts
Public ContactGong Yuping
West China Hospital, Sichuan University
Outcome results
None listed